Buprenorphine Treatment in Pregnancy and Maternal-Infant Outcomes
(Abstracted from JAMA Health Forum 2025;6(4.11):e251814) Between 1999 and 2017, the number of pregnant people with opioid use disorder (OUD) increased from 1.5 to 8.2 per 1000 delivery hospitalizations in the United States. The American College of Obstetrics and Gynecology and the Substance Abuse and Mental Health Administration endorse the use of either methadone, a full μ-opioid receptor agonist, or buprenorphine, a partial μ-opioid receptor agonist and full κ-receptor antagonist, to treat OUD in pregnancy.
Authors
- Ashley A. Leech (ORCID: https://orcid.org/0000-0001-6795-929X)
- Andrew David Wiese (ORCID: https://orcid.org/0000-0002-0699-4224)
- Thomas S. Reese (ORCID: https://orcid.org/0000-0002-1081-1670)
- Elizabeth McNeer
- Stephen W. Patrick (ORCID: https://orcid.org/0000-0001-6958-0371)
- Julia C. Phillippi (ORCID: https://orcid.org/0000-0002-6549-094X)
- William D. Dupont (ORCID: https://orcid.org/0000-0002-8166-599X)
- Judith A. Dudley
- Sarah F. Loch (ORCID: https://orcid.org/0000-0001-5500-4680)
- Sunaya R. Krishnapura
Publication Details
- Journal
- Obstetrical & Gynecological Survey
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1097/01.ogx.0001169612.88317.48
- Primary Topic
- Prenatal Substance Exposure Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00